Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Meric

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Breast (Edinburgh, Scotland)|June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity studyG Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationS Fu, M M Hou, A Naing, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
Annals of Surgical Oncology|July 14, 2000
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancerF Meric, N Q Mirza, A U Buzdar, et al.
ESMO Open|August 1, 2024
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignanciesG Curigliano, M M Jimenez, T Shimizu, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Annals of Surgical Oncology|December 18, 2018
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer PatientsS E Tevis, R Bassett, I Bedrosian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trialR Lesurf, O L Griffith, M Griffith, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Breast (Edinburgh, Scotland)|June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity studyG Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationS Fu, M M Hou, A Naing, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
Annals of Surgical Oncology|July 14, 2000
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancerF Meric, N Q Mirza, A U Buzdar, et al.
ESMO Open|August 1, 2024
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignanciesG Curigliano, M M Jimenez, T Shimizu, et al.
ESMO Open|May 13, 2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancerM A Gouda, M H Voss, H Tawbi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Annals of Surgical Oncology|December 18, 2018
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer PatientsS E Tevis, R Bassett, I Bedrosian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trialR Lesurf, O L Griffith, M Griffith, et al.
Pageof 7